Drug Interactions between Copper and vadadustat

Using vadadustat while smoking or drinking alcohol may increase the risk of side effects in the gastrointestinal tract such as stomach inflammation and bleeding. Talk to your doctor if you have any questions or concerns. You should seek immediate medical attention if you have signs and symptoms of gastrointestinal bleeding such as abdominal pain, coughing up or vomiting fresh or dried blood that looks like coffee grounds, black, tarry stools, trouble swallowing, or chest or throat pain. It is important to tell your doctor about all other medications you use, including vitamins and herbs. Do not stop using any medications without first talking to your doctor.

Vadadustat is contraindicated in patients with uncontrolled hypertension as cases of hypertensive crisis including hypertensive encephalopathy and seizures have been reported. Patients with history of seizure disorders receiving this drug should be monitored closely and should contact their health care provider for premonitory symptoms or change in seizure frequency.

Vadadustat is contraindicated in patients with uncontrolled hypertension as cases of hypertensive crisis including hypertensive encephalopathy and seizures have been reported. Patients with history of seizure disorders receiving this drug should be monitored closely and should contact their health care provider for premonitory symptoms or change in seizure frequency.

Esophageal and gastrointestinal erosions have been reported with the use of vadadustat. Some cases of serious gastrointestinal bleeding required the need for red blood cell transfusions. Patients with history of gastrointestinal erosion, peptic ulcer disease, tobacco smokers and alcohol drinkers are at increased risk.

The trace elements, copper and manganese, are excreted in the bile. Copper and manganese doses may need to be adjusted, reduced, or omitted in patients with liver disease or biliary obstruction.

An increase in hypoxia inducible factor (HIF) levels may be associated with unfavorable effects on cancer growth. The use of vadadustat has not been studied and is not recommended in patients with active malignancies.

An increase in hypoxia inducible factor (HIF) levels may be associated with unfavorable effects on cancer growth. The use of vadadustat has not been studied and is not recommended in patients with active malignancies.

Vadadustat increases the risk of arterial and venous thrombotic events, including major adverse cardiovascular events. Patients with cardiovascular or cerebrovascular disease are at increased risk. Avoid the use of this drug in patients with history of myocardial infarction, cerebrovascular events, or acute coronary syndrome within the 3 months prior to starting treatment.

Esophageal and gastrointestinal erosions have been reported with the use of vadadustat. Some cases of serious gastrointestinal bleeding required the need for red blood cell transfusions. Patients with history of gastrointestinal erosion, peptic ulcer disease, tobacco smokers and alcohol drinkers are at increased risk.

Esophageal and gastrointestinal erosions have been reported with the use of vadadustat. Some cases of serious gastrointestinal bleeding required the need for red blood cell transfusions. Patients with history of gastrointestinal erosion, peptic ulcer disease, tobacco smokers and alcohol drinkers are at increased risk.

The trace elements, copper and manganese, are excreted in the bile. Copper and manganese doses may need to be adjusted, reduced, or omitted in patients with liver disease or biliary obstruction.

Vadadustat may cause hepatotoxicity. Liver enzymes and bilirubin should be measured prior to treatment initiation and monitored during treatment. This drug is not recommended in patients with cirrhosis, or active, acute liver disease.

An increase in hypoxia inducible factor (HIF) levels may be associated with unfavorable effects on cancer growth. The use of vadadustat has not been studied and is not recommended in patients with active malignancies.

The trace metals manganese, chromium, copper, selenium, and zinc are absorbed in the GI tract from dietary sources and following administration of oral supplements. GI absorption may be decreased in patients with malabsorption syndromes. Therefore, larger dosages may be required when these supplements are given orally. Parenteral administration may be appropriate.

An increase in hypoxia inducible factor (HIF) levels may be associated with unfavorable effects on cancer growth. The use of vadadustat has not been studied and is not recommended in patients with active malignancies.

An increase in hypoxia inducible factor (HIF) levels may be associated with unfavorable effects on cancer growth. The use of vadadustat has not been studied and is not recommended in patients with active malignancies.

Esophageal and gastrointestinal erosions have been reported with the use of vadadustat. Some cases of serious gastrointestinal bleeding required the need for red blood cell transfusions. Patients with history of gastrointestinal erosion, peptic ulcer disease, tobacco smokers and alcohol drinkers are at increased risk.